Monitor the company's stock price for any sustained recovery above $1.00 over ten consecutive business days. The next key date is April 5, 2027, when the initial compliance period expires. A reverse stock split is a likely remedy if the price does not recover organically.
Price Chart
Executive Summary
CytoMed Therapeutics received a Nasdaq deficiency notice on October 6, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive business days (August 24 to October 5, 2026). The company has until April 5, 2027, to regain compliance, with a potential additional 180-day period if it meets other listing standards. This is a routine delisting-risk event for a clinical-stage biotech with no revenue, and the stock has historically not reacted positively to prior filings.
Key Facts
- Nasdaq notified CytoMed on October 6, 2026, of non-compliance with the $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).
- The non-compliance period covered 30 consecutive business days from August 24, 2026, to October 5, 2026.
- The company has a 180-day compliance period ending April 5, 2027, to regain compliance.
- If compliance is not achieved by April 5, 2027, the company may be eligible for an additional 180-day period if it meets other Nasdaq Capital Market listing standards.
- The company is considering all options, including a potential reverse stock split, to cure the deficiency.
Financial Impact
No financial figures provided in the filing; the event is a delisting-risk notification with no immediate operational impact.
Risk Factors
- Failure to regain compliance could lead to delisting from Nasdaq, reducing liquidity and investor confidence.
- A reverse stock split, if implemented, may be viewed negatively by the market and could further pressure the stock price.
- As a clinical-stage biotech with no revenue, the company has limited fundamental catalysts to drive the stock price above $1.00.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-046630 |
| Exhibit: ex99-1.htm | 0001493152-26-046630 |
| Document: 0001493152-26-046630-index-headers.html | 0001493152-26-046630 |
| Document: 0001493152-26-046630-index.html | 0001493152-26-046630 |
| Document: 0001493152-26-046630.txt | 0001493152-26-046630 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G/A | $0.9190 $0.9262 | ▲ +0.78% | ▲ +0.07% | $0.9262 (+0.78%) |
Oct 16, 2026 10d ago | SC 13D/A | $0.8799 $0.8520 | ▼ −3.17% | ▼ −3.59% | $0.9262 (+5.26%) |
Oct 13, 2026 13d ago | SC 13D/A | $0.8700 $0.8599 | ▼ −1.16% | ▼ −0.08% | $0.9262 (+6.46%) |
Oct 9, 2026 16d ago | 6-K | $0.8114 $0.8700 | ▼ −7.22% | ▼ −7.23% | $0.9262 (−14.15%) |
Sep 30, 2026 26d ago | 6-K | $0.8430 $0.8999 | ▼ −6.75% | ▼ −6.57% | $0.9262 (−9.87%) |
May 15, 2026 23w ago | 6-K | $1.16 $1.21 | ▲ +4.31% | ▲ +4.37% | $0.9262 (−20.16%) |
May 11, 2026 24w ago | 6-K | $0.8090 $0.7690 | ▼ −4.94% | ▼ −4.81% | $0.9262 (+14.49%) |
Mar 31, 2026 29w ago | 6-K | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.9262 (−7.38%) |
Mar 31, 2026 29w ago | 20-F | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.9262 (−7.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers